Joshua B Cohen sold $429k of AMLX
Co-Chief Executive Officer at Amylyx Pharmaceuticals, Inc.. 29,933 shares at an average of $14.35, traded Sep 30, 2025, filed Oct 2, 2025.
Score components
- +25RoleCEO
- +17Trade size$429k at market
- 0Share of holdings soldSold 0.9% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-228340, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2025 | SOpen-market sale Common Stock | -29,733 | $14.34 | $426k | 3,325,547 | Oct 2, 2025 |
| Sep 30, 2025 | SOpen-market sale Common Stock | -200 | $15.00 | $3,000 | 3,325,347 | Oct 2, 2025 |
Related signals
Other insiders at Amylyx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | Amylyx Pharmaceuticals, Inc. | George M Milne Jr director | $831k 30,000 shares | -4% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Justin B. Klee Co-Chief Executive Officer | $980k 30,464 shares | -1% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Joshua B Cohen Co-Chief Executive Officer | $981k 30,464 shares | -1% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $310k 9,536 shares | -5% | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $350k 10,810 shares | -4% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $325k 10,028 shares | -3% | |
| 32Weak | AMLXbuy Amylyx Pharmaceuticals, Inc. | Karen Firestone director | $101k 8,100 shares | +15% | |
| 25Weak | AMLXsell Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $94k 6,580 shares | -4% | |
| 42Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $176k 12,039 shares | -6% | |
| 48Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $155k 10,558 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.